Searchable abstracts of presentations at key conferences in endocrinology

ea0091wd2 | Workshop D: Disorders of the adrenal gland | SFEEU2023

Composite Pheochromocytoma with Adrenocortical Carcinoma - a rare coexistence

Sarwani Aysha , Morrin Martina , Naidoo Jarushka , O'Brien Odharnaith , Skordilis Kassi , Ryan Cliona , Dugal Neal , Hill Arnold , Srinivasan Shari , Sherlock Mark , O'Reilly Michael

A 65-year-old man presenting with urinary symptoms was incidentally discovered to have an adrenal mass on imaging. Abdominal computed tomography (CT) revealed a 9.5 x 8 cm heterogenous solid right adrenal tumour with no evidence of metastatic disease. Family history included a brother who died from metastatic carcinoid and another brother who died from metastatic neuroendocrine tumour. The initial differential lay between adrenocortical carcinoma (ACC) or a pheochromocytoma. T...

ea0049ep798 | Neuroendocrinology | ECE2017

Dissecting the androgen excess phenotype of women with idiopathic intracranial hypertension

O'Reilly Michael , Hornby Catherine , Westgate Connar , Botfield Hannah , Markey Keira , Jenkinson Carl , Gilligan Lorna , Sherlock Mark , Gibney James , Tomlinson Jeremy , Arlt Wiebke , Sinclair Alexandra

Abstract: Idiopathic intracranial hypertension (IIH) is a devastating neurological condition, with elevated intracranial pressure of unknown aetiology. IIH is largely a disease of obese females of reproductive age. The clinical phenotype of IIH overlaps with polycystic ovary syndrome (PCOS), with prevalent obesity, hyperandrogenism and anovulation. In this study, we aimed to delineate the androgen excess phenotype of IIH women compared to those with PCOS and simple obesity. Wo...

ea0049ep1150 | Female Reproduction | ECE2017

Biochemical and clinical characteristics of polysystic ovarian syndrome (PCOS) in women with and without type 1 diabetes (TID)

Gunness Anjuli , Pazderska Agnieska , Ahmed Mohamed , Phelan Niamh , Boran Gerard , Taylor AE , O'Reilly MW , Arlt Wiebke , Moore Kevin , Behan Lucy-Ann , Sherlock Mark , Gibney James

Abstract: PCOS prevalence is reported to be increased in reproductive-age women with type-1 diabetes (T1DM) but measurement of androgens, crucial for diagnosis, has been with inaccurate immunoassays. No studies have been reported using liquid-chromatography-mass-spectrometry (LCMS). Reproductive-age T1DM women attending a single centre were evaluated for PCOS (NIH criteria). Women with T1DM and PCOS (T1/PCOS) were compared to T1DM women without hyperandrogenism (T1/no HA), and...

ea0049ep1153 | Female Reproduction | ECE2017

Androgen profiling by liquid chromatography-mass spectrometry (LC-MS) in reproductive-age women with and without diabetes

Gunness Anjuli , Pazderska Agnieska , Ahmed Mohamed , Phelan Niamh , Boran Gerard , Taylor AE , O'Reilly MW , Arlt Wiebke , Moore Kevin , Behan Lucy-Ann , Sherlock Mark , Gibney James

Abstract: The prevalence of hyperandrogenism has been reported to be increased in reproductive-age women with type-1 diabetes (T1DM). This observation however is based on findings using inaccurate immunoassays. No studies have been reported in diabetes using liquid-chromatography-mass-spectrometry (LCMS). We compared LCMS-measured androgens in T1DM-women with age-/ BMI-matched normal women, and compared findings with those in women with type-2 diabetes (T2DM) also compared to ...

ea0037gp.04.02 | Steroids | ECE2015

The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure

Sherlock Mark , Behan Lucy Ann , Hannon Mark , Alonso Aurora Aragon , Thompson Christopher , Murray Robert , Crabtree Nicola , Hughes Beverly , Arlt Wiebke , Agha Amar , Toogood Andrew , Stewart Paul M

Context: Patients with hypopituitarism have increased morbidity and mortality. There is ongoing debate around the optimum glucocorticoid replacement therapy.Objective: To assess the effect of glucocorticoid replacement in hypopituitarism on corticosteroid metabolism and its impact on body composition.Design and patients: We assessed the urinary corticosteroid metabolite profile (using gas chromatography/mass spectrometry) and body ...

ea0070oc4.7 | Pituitary and Neuroendocrinology | ECE2020

Fluid restriction results in a modest rise in plasma sodium concentration in chronic hyponatraemia due to SIAD; results of a prospective randomised controlled trial

Garrahy Aoife , Galloway Iona , Hannon Anne Marie , Dineen Rosemary , O’Kelly Patrick , Tormey William , O’Reilly Michael , Williams David , Sherlock Mark , Thompson Chris

Fluid restriction (FR) is the recommended first-line treatment for chronic hyponatraemia due to syndrome of inappropriate antidiuresis (SIAD) in expert guidelines, despite the lack of prospective data to support its efficacy. We aimed to test the hypothesis that FR was more effective than no treatment. 46 patients with chronic SIAD were randomised to either fluid restriction (1 litre/day, FR) or no specific hyponatraemia treatment (NoTx) for one month. Inclusion criteria were ...

ea0016p468 | Neuroendocrinology | ECE2008

Factors associated with response to medical therapy in patients with Acromegaly

Fernandez-Rodriguez Eva , Sherlock Mark , Aragon Alonso Aurora , Ayuk John , Clayton Richard N , Sheppard Michael C , Bates Andy , Stewart Paul M

Acromegaly is associated with increased morbidity and mortality. Surgery, radiotherapy (RT) and medical therapy are the treatment options to decrease GH and IGF-I concentrations to levels associated with cure or normalisation of mortality. We examined the response to dopamine agonists (DA) and somatostatin analogues (SSA) in 276 patients with acromegaly who received medical therapy during follow up (198 DA, 143 SSA). One hundred and seventy two had surgery and 73 RT prior to m...

ea0015p260 | Pituitary | SFEBES2008

Predictors of response to medical therapy in patients with acromegaly

Sherlock Mark , Fernandez-Rodriguez Eva , Alonso Aurora Aragon , Ayuk John , Clayton Richard N , Sheppard Michael C , Bates Andy , Stewart Paul M

Acromegaly is associated with increased morbidity and mortality. There are several treatment options for acromegaly including surgery, radiotherapy and medical therapy. The aims of treatment in patients with acromegaly is to achieve GH and IGF-I concentrations associated with cure or normalisation of mortality.We examined predictive factors of response to treatment with dopamine agonists (DA) and somatostatin analogues (SSA) in a cohort of 501 patients w...

ea0015p261 | Pituitary | SFEBES2008

Effect of radiotherapy and pituitary dysfunction on mortality in patients with acromegaly

Sherlock Mark , Alonso Aurora Aragon , Reulen Raoul C , Ayuk John , Clayton Richard N , Sheppard Michael C , Hawkins Mike , Bates Andy , Stewart Paul M

Acromegaly is associated with increased morbidity and premature mortality which has been demonstrated in a number of retrospective studies reporting a standardised mortality ratio (SMR) between 1.3 and 3. Many patients with acromegaly develop hypopituitarism as a result of the pituitary adenoma itself or surgery and/or radiotherapy. Hypopituitarism is also associated with an increased SMR (1.2–2.17).Using the West Midlands Acromegaly database (n<...

ea0011p607 | Neuroendocrinology and behaviour | ECE2006

Hypothalamic-pituitary dysfunction following irradiation of non-pituitary brain tumours in adults

Agha A , Sherlock M , Brennan S , O’Connor SA , O’Sullivan E , Rogers B , Faul C , Rawluk D , Tormey W , Thompson C.J.

Hypothalamic-pituitary (HP) dysfunction is common in children treated with cranial radiotherapy (RT) for brain tumours but there is little known about the risk of HP dysfunction in adults treated with RT for primary non-pituitary brain tumours.We aimed to investigate the frequency of HP dysfunction in adults after RT for primary brain tumours which are distant from the HP region.We studied 56 adult patients who received external be...